Breast cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related mortality among women in the US.
mandated cross-over in the single-agent arm. Therefore, sequential monotherapy tends to be favored in order to minimize toxicity and maximize patients' quality of life. The present article provides an overview of the currently available chemotherapy options for MBC patients following treatment with A/T-based regimens. Table 3 12 lists the key features and mechanisms of action of the drugs reviewed.
Options for Monotherapy

Capecitabine
Capecitabine is an oral pro-drug that is preferentially converted to the antimetabolite 5-fluorouracil by thymidine phosphorylase, an enzyme found at higher levels in tumor cells versus normal cells (see Table 3 ). 13, 14 Single-agent capecitabine was approved in 1998 for use as second-or third-line treatment for MBC following disease progression on A/T-based regimens. The pivotal trial was a multicenter, single-arm Phase II trial conducted in paclitaxel-refractory MBC patients (n=162), 91 % of whom had previously received an anthracycline. 15 The ORR was found to be 20 %, and all responders had previously received an anthracycline.
Median TTP was 3.0 months, and median OS was 12.8 months. The efficacy of single-agent capecitabine is supported by several other Phase II studies. [16] [17] [18] [19] [20] The trials and pertinent findings are summarized in Table 4 .
Frequently reported grade 3/4 adverse events associated with capecitabine include palmar-plantar erythrodysesthesia and diarrhea. 13, 20 Nausea, emesis, and stomatitis (all grades) were also reported, 16 but the majority of toxicities were mild-to-moderate in severity, with few grade 4 adverse events. In addition, myelosuppression and alopecia were rare, and there were no documented treatment-related deaths.
In an effort to improve the tolerability of capecitabine, investigators conducted a safety study in which a reduction from the FDA-approved dose of 1,250 mg/m 2 orally twice daily to a dose of 1,000 mg/m 2 orally twice daily for 14 days in 21-day cycles decreased the incidence of adverse events-with the notable exception of palmar-plantar erythrodysesthesia-in patients with MBC. 21 Importantly, clinical benefit was retained despite the reduced dose, and 65 % of the subjects had prior A/T-based therapy. 21 
Ixabepilone
Ixabepilone is a semi-synthetic analog of epothilone B. It binds directly to the β-tubulin structure on microtubules, leading to microtubule stabilization, cell-cycle arrest, and cytotoxicity (see Table 3 ). 12, 22 The β-tubulin binding site for epothilones differs from that for taxanes, so the selective mechanisms for inducing apoptosis are similar but not identical to those of paclitaxel and docetaxel. In addition, epothilones are not influenced by the resistance mechanisms known to reduce the activity of taxanes and anthracyclines (e.g., p-glycoprotein, multidrug resistance protein 1, and breast cancer resistance protein), which may provide an advantage over these standard agents. 23, 24 Single-agent ixabepilone demonstrated activity in a series of Phase II studies in A/T-pre-treated MBC. Patients (n=49) whose disease progressed while receiving, or within four months of receiving, 
Eribulin
Eribulin mesylate is a synthetic analog of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. It is a novel non-taxane microtubule dynamics inhibitor; it blocks microtubule polymerization without affecting de-polymerization, inducing G2-M phase arrest and subsequent apoptosis (see Table 3 11 ). 27 In vitro studies revealed that the activity of eribulin is more specific compared with other tubulin-targeting agents. 28 This degree of specificity is achieved by its ability to bind selectively and with high affinity to the growing plus ends of microtubules, suppressing dynamic instability.
In mouse studies, eribulin was associated with less neuropathy than equivalent maximum tolerated dose-based amounts of paclitaxel or ixabepilone. 29 These findings were substantiated in human subjects.
In a randomized Phase II study of eribulin versus ixabepilone, eribulin led to fewer neuropathic adverse events, although the difference was not statistically significant. 30 Three Phase II studies investigated the efficacy and tolerability of eribulin in heavily pre-treated MBC patients. [31] [32] [33] An open-label, single-arm Phase II study accrued 103 MBC patients who had received a median of four prior chemotherapy regimens (including an anthracycline and a taxane). 31 Eribulin was associated with an independently reviewed ORR of 11.5 %, median PFS of 2.6 months, and median OS of 9.0 months, with no reported grade 4 neuropathy. The most common grade 3/4 toxicities associated with eribulin included peripheral neuropathy, neutropenia, leucopenia, and fatigue.
Treatment discontinuation due to adverse events occurred in 13 % of patients on eribulin and 15 % of patients on TPC. Peripheral neuropathy was the most common adverse event associated with discontinuation of eribulin (5 %). 34 To date, eribulin is the only single agent that has been shown to prolong OS in heavily pre-treated MBC patients. Therefore, the updated National Comprehensive Cancer Network (NCCN) guidelines list it as a preferred monotherapy for patients previously treated with at least two chemotherapeutic regimens for advanced disease. 7 
Vinorelbine
Vinorelbine is a semi-synthetic vinca alkaloid that suppresses microtubule formation by binding to tubulin monomers, resulting in cytotoxicity (see Table 3 ). 36 Several clinical studies have reported on its efficacy in the treatment of A/T-refractory MBC. 37, 38 
Ixabepilone plus Capecitabine
A Phase I/II study of 62 patients with A/T-pre-treated MBC reported a median ORR of 30 % and a median PFS of 3.8 months with the combination of ixabepilone plus capecitabine. 43 In 
Gemcitabine-based Combinations
Gemcitabine is a nucleoside analog that becomes phosphorylated within cells and incorporated into DNA as a triphosphate (see Table 3 ). Response rates with single-agent gemcitabine are 14-37 % in patients not previously exposed to chemotherapy and 12-30 % in patients treated with prior anthracyclines and/or taxanes.
In terms of combination regimens, gemcitabine was evaluated in combination with carboplatin in a Phase II study of patients with hormone receptor-negative, HER2-negative MBC pre-treated with A/T. 46 The ORR was 32 %, median TTP was 5.5 months, and median OS was 11 months. Gemcitabine plus carboplatin is therefore considered a suitable option in this subset of patients.
In another Phase II trial, pre-treated MBC patients were randomized to receive bi-weekly gemcitabine plus either paclitaxel, carboplatin, or cisplatin as first-line treatment. 47 The ORRs were 26.5 %, 17.0 %, and 15.7 % for gemcitabine plus paclitaxel, gemcitabine plus carboplatin, and gemcitabine plus cisplatin, respectively. No significant differences were observed in median OS (15.5, 22.8, and 20.1 months, respectively) or median PFS (4.8, 4.3, and 4.8 months, respectively). All three chemotherapy doublets had comparable tolerability; the most commonly reported drug-related adverse events among all subjects were nausea (54.1 %), vomiting (42.5 %), alopecia (42.5 %), and fatigue (29.5 %).
Rechallenging with Anthracyclines or Taxanes
Anthracyclines and taxanes are key treatment options in the management of breast cancer and, in recent years, their use in the adjuvant setting has increased greatly. 48 While this has resulted in considerable benefits in terms of disease-free survival (DFS) and OS in early-stage disease, 49 
